Cargando…

Pharmacokinetic Properties of Ibuprofen (IBU) From the Fixed‐Dose Combination IBU/Caffeine (400/100 mg; FDC) in Comparison With 400 mg IBU as Acid or Lysinate Under Fasted and Fed Conditions—Data From 2 Single‐Center, Single‐Dose, Randomized Crossover Studies in Healthy Volunteers

Rapid onset of analgesic action is linked with rapid absorption of analgesics (high maximum concentration [C(max)] and short time to maximum concentration [t(max)]). After overnight fasting, ibuprofen lysinate reaches higher peak plasma levels (C(max)) earlier than ibuprofen acid (t(max)) with compa...

Descripción completa

Detalles Bibliográficos
Autores principales: Weiser, Thomas, Schepers, Cornelia, Mück, Tobias, Lange, Robert
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6767367/
https://www.ncbi.nlm.nih.gov/pubmed/30897305
http://dx.doi.org/10.1002/cpdd.672
_version_ 1783454901481766912
author Weiser, Thomas
Schepers, Cornelia
Mück, Tobias
Lange, Robert
author_facet Weiser, Thomas
Schepers, Cornelia
Mück, Tobias
Lange, Robert
author_sort Weiser, Thomas
collection PubMed
description Rapid onset of analgesic action is linked with rapid absorption of analgesics (high maximum concentration [C(max)] and short time to maximum concentration [t(max)]). After overnight fasting, ibuprofen lysinate reaches higher peak plasma levels (C(max)) earlier than ibuprofen acid (t(max)) with comparable exposure (area under the plasma concentration–time curve [AUC]); however, subjects usually take ibuprofen with or within a short time of a meal. Therefore, pharmacokinetic (PK) studies under fed conditions may better characterize properties under real‐life conditions. We investigated a new fixed‐dose combination (FDC) of ibuprofen acid 400 mg and caffeine 100 mg in 2 single‐dose, randomized, crossover PK studies in healthy subjects (both N = 36). The FDC was compared with ibuprofen 400 mg as acid and as lysinate after an overnight fast in Study 1, and with ibuprofen lysinate after a meal in Study 2. After fasting, results for ibuprofen in the FDC were comparable with those from ibuprofen acid alone. Caffeine did not affect the C(max), t(max), and AUC. As expected, a higher C(max) and shorter t(max) were observed with ibuprofen lysinates vs the FDC. Compared with administration after fasting, C(max) and t(max) for ibuprofen lysinate administered postprandially were markedly different, while with FDC, these parameters were less sensitive to food intake. Taken after a meal, ibuprofen in the FDC reached t(max) earlier than ibuprofen lysinate (median 1.25 vs 1.63 hours), and C(max) was approximately 13% higher, with comparable AUC, suggesting that the profile of ibuprofen was in favor of the FDC compared with ibuprofen lysinate. Thus, under real‐life conditions, ibuprofen lysinate had no PK advantage over the FDC. All preparations were well tolerated.
format Online
Article
Text
id pubmed-6767367
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-67673672019-10-03 Pharmacokinetic Properties of Ibuprofen (IBU) From the Fixed‐Dose Combination IBU/Caffeine (400/100 mg; FDC) in Comparison With 400 mg IBU as Acid or Lysinate Under Fasted and Fed Conditions—Data From 2 Single‐Center, Single‐Dose, Randomized Crossover Studies in Healthy Volunteers Weiser, Thomas Schepers, Cornelia Mück, Tobias Lange, Robert Clin Pharmacol Drug Dev Articles Rapid onset of analgesic action is linked with rapid absorption of analgesics (high maximum concentration [C(max)] and short time to maximum concentration [t(max)]). After overnight fasting, ibuprofen lysinate reaches higher peak plasma levels (C(max)) earlier than ibuprofen acid (t(max)) with comparable exposure (area under the plasma concentration–time curve [AUC]); however, subjects usually take ibuprofen with or within a short time of a meal. Therefore, pharmacokinetic (PK) studies under fed conditions may better characterize properties under real‐life conditions. We investigated a new fixed‐dose combination (FDC) of ibuprofen acid 400 mg and caffeine 100 mg in 2 single‐dose, randomized, crossover PK studies in healthy subjects (both N = 36). The FDC was compared with ibuprofen 400 mg as acid and as lysinate after an overnight fast in Study 1, and with ibuprofen lysinate after a meal in Study 2. After fasting, results for ibuprofen in the FDC were comparable with those from ibuprofen acid alone. Caffeine did not affect the C(max), t(max), and AUC. As expected, a higher C(max) and shorter t(max) were observed with ibuprofen lysinates vs the FDC. Compared with administration after fasting, C(max) and t(max) for ibuprofen lysinate administered postprandially were markedly different, while with FDC, these parameters were less sensitive to food intake. Taken after a meal, ibuprofen in the FDC reached t(max) earlier than ibuprofen lysinate (median 1.25 vs 1.63 hours), and C(max) was approximately 13% higher, with comparable AUC, suggesting that the profile of ibuprofen was in favor of the FDC compared with ibuprofen lysinate. Thus, under real‐life conditions, ibuprofen lysinate had no PK advantage over the FDC. All preparations were well tolerated. John Wiley and Sons Inc. 2019-03-21 2019 /pmc/articles/PMC6767367/ /pubmed/30897305 http://dx.doi.org/10.1002/cpdd.672 Text en © 2019 The Authors. Clinical Pharmacology in Drug Development Published by Wiley Periodicals, Inc. on behalf of The American College of Clinical Pharmacology This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.
spellingShingle Articles
Weiser, Thomas
Schepers, Cornelia
Mück, Tobias
Lange, Robert
Pharmacokinetic Properties of Ibuprofen (IBU) From the Fixed‐Dose Combination IBU/Caffeine (400/100 mg; FDC) in Comparison With 400 mg IBU as Acid or Lysinate Under Fasted and Fed Conditions—Data From 2 Single‐Center, Single‐Dose, Randomized Crossover Studies in Healthy Volunteers
title Pharmacokinetic Properties of Ibuprofen (IBU) From the Fixed‐Dose Combination IBU/Caffeine (400/100 mg; FDC) in Comparison With 400 mg IBU as Acid or Lysinate Under Fasted and Fed Conditions—Data From 2 Single‐Center, Single‐Dose, Randomized Crossover Studies in Healthy Volunteers
title_full Pharmacokinetic Properties of Ibuprofen (IBU) From the Fixed‐Dose Combination IBU/Caffeine (400/100 mg; FDC) in Comparison With 400 mg IBU as Acid or Lysinate Under Fasted and Fed Conditions—Data From 2 Single‐Center, Single‐Dose, Randomized Crossover Studies in Healthy Volunteers
title_fullStr Pharmacokinetic Properties of Ibuprofen (IBU) From the Fixed‐Dose Combination IBU/Caffeine (400/100 mg; FDC) in Comparison With 400 mg IBU as Acid or Lysinate Under Fasted and Fed Conditions—Data From 2 Single‐Center, Single‐Dose, Randomized Crossover Studies in Healthy Volunteers
title_full_unstemmed Pharmacokinetic Properties of Ibuprofen (IBU) From the Fixed‐Dose Combination IBU/Caffeine (400/100 mg; FDC) in Comparison With 400 mg IBU as Acid or Lysinate Under Fasted and Fed Conditions—Data From 2 Single‐Center, Single‐Dose, Randomized Crossover Studies in Healthy Volunteers
title_short Pharmacokinetic Properties of Ibuprofen (IBU) From the Fixed‐Dose Combination IBU/Caffeine (400/100 mg; FDC) in Comparison With 400 mg IBU as Acid or Lysinate Under Fasted and Fed Conditions—Data From 2 Single‐Center, Single‐Dose, Randomized Crossover Studies in Healthy Volunteers
title_sort pharmacokinetic properties of ibuprofen (ibu) from the fixed‐dose combination ibu/caffeine (400/100 mg; fdc) in comparison with 400 mg ibu as acid or lysinate under fasted and fed conditions—data from 2 single‐center, single‐dose, randomized crossover studies in healthy volunteers
topic Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6767367/
https://www.ncbi.nlm.nih.gov/pubmed/30897305
http://dx.doi.org/10.1002/cpdd.672
work_keys_str_mv AT weiserthomas pharmacokineticpropertiesofibuprofenibufromthefixeddosecombinationibucaffeine400100mgfdcincomparisonwith400mgibuasacidorlysinateunderfastedandfedconditionsdatafrom2singlecentersingledoserandomizedcrossoverstudiesinhealthyvolunteers
AT scheperscornelia pharmacokineticpropertiesofibuprofenibufromthefixeddosecombinationibucaffeine400100mgfdcincomparisonwith400mgibuasacidorlysinateunderfastedandfedconditionsdatafrom2singlecentersingledoserandomizedcrossoverstudiesinhealthyvolunteers
AT mucktobias pharmacokineticpropertiesofibuprofenibufromthefixeddosecombinationibucaffeine400100mgfdcincomparisonwith400mgibuasacidorlysinateunderfastedandfedconditionsdatafrom2singlecentersingledoserandomizedcrossoverstudiesinhealthyvolunteers
AT langerobert pharmacokineticpropertiesofibuprofenibufromthefixeddosecombinationibucaffeine400100mgfdcincomparisonwith400mgibuasacidorlysinateunderfastedandfedconditionsdatafrom2singlecentersingledoserandomizedcrossoverstudiesinhealthyvolunteers